Assembly Bio Narrows Q3 Loss, Secures $175M Funding Round

Ticker: ASMB · Form: 10-Q · Filed: 2025-11-10T00:00:00.000Z

Sentiment: bullish

Topics: Biotechnology, Clinical Trials, Equity Offering, Liquidity, Viral Diseases, Research & Development, Collaboration Revenue

Related Tickers: ASMB, GILD

TL;DR

**Assembly Bio's massive $175M raise and improved revenue signal a strong buy, as liquidity concerns are now off the table for this biotech player.**

AI Summary

ASSEMBLY BIOSCIENCES, INC. reported a net loss of $9.196 million for the three months ended September 30, 2025, a slight improvement from the $9.613 million net loss in the same period of 2024. For the nine months ended September 30, 2025, the net loss was $28.212 million, down from $29.842 million in 2024. Collaboration revenue from a related party increased significantly to $10.789 million for the three months ended September 30, 2025, up from $6.845 million in 2024, and to $29.834 million for the nine months, up from $21.163 million. Research and development expenses rose to $16.587 million for the quarter and $47.563 million for the nine months, reflecting ongoing product development. The company successfully raised $175.0 million in August 2025 through an underwritten offering and a private placement, boosting cash, cash equivalents, and marketable securities to $232.6 million as of September 30, 2025. This capital infusion resolved previous substantial doubt about its ability to continue as a going concern, providing liquidity beyond one year.

Why It Matters

This filing is crucial for investors as Assembly Biosciences, a clinical-stage biotechnology company, has significantly improved its liquidity position by raising $175.0 million in August 2025. This capital infusion, which increased cash, cash equivalents, and marketable securities to $232.6 million, has resolved the 'going concern' doubt, providing a runway for its ambitious pipeline targeting herpes simplex virus, hepatitis delta virus, and hepatitis B virus. The increased collaboration revenue also signals progress in its strategic partnerships, potentially strengthening its competitive stance against other antiviral developers. Employees and customers benefit from the enhanced financial stability, which supports continued research and development efforts for new therapeutic options in serious viral diseases.

Risk Assessment

Risk Level: medium — The company continues to incur substantial losses, with a net loss of $28.212 million for the nine months ended September 30, 2025, and has not generated revenue from product sales to date. While the recent $175.0 million capital raise provides liquidity beyond one year, the long-term financial viability still depends on successful clinical development and regulatory approval of its product candidates, which are inherently uncertain and costly.

Analyst Insight

Investors should consider this a positive development, as the significant capital raise of $175.0 million has de-risked the immediate liquidity concerns for Assembly Biosciences. Monitor the progress of their clinical trials, particularly the helicase-primase inhibitors for HSV and the hepatitis delta virus entry inhibitor, as successful trial outcomes will be the next major catalyst for sustained growth and potential profitability.

Financial Highlights

debt To Equity
N/A
revenue
$10.789M
operating Margin
N/A
total Assets
N/A
total Debt
N/A
net Income
-$9.196M
eps
N/A
gross Margin
N/A
cash Position
$232.6M
revenue Growth
+57.6%

Revenue Breakdown

SegmentRevenueGrowth
Collaboration Revenue$10.789M+57.6%
Collaboration Revenue (9 months)$29.834M+41.2%

Key Numbers

Key Players & Entities

FAQ

What was Assembly Biosciences' net loss for the third quarter of 2025?

Assembly Biosciences reported a net loss of $9.196 million for the three months ended September 30, 2025, which is an improvement compared to the $9.613 million net loss in the same period of 2024.

How much capital did Assembly Biosciences raise in August 2025?

In August 2025, Assembly Biosciences raised aggregate gross proceeds of $175.0 million from the sale of common stock, pre-funded warrants, and warrants through an underwritten offering and a private placement.

What is Assembly Biosciences' cash position as of September 30, 2025?

As of September 30, 2025, Assembly Biosciences held cash, cash equivalents, and marketable securities totaling $232.6 million, a significant increase from $112.079 million at December 31, 2024.

Did Assembly Biosciences resolve its going concern uncertainty?

Yes, management believes that the $175.0 million capital raise in August 2025 has provided sufficient funds to meet its operating requirements beyond one year, thereby resolving the conditions which previously raised substantial doubt about its ability to continue as a going concern.

What was the collaboration revenue for Assembly Biosciences for the nine months ended September 30, 2025?

For the nine months ended September 30, 2025, Assembly Biosciences' collaboration revenue from a related party was $29.834 million, an increase from $21.163 million in the same period of 2024.

What are the key therapeutic areas Assembly Biosciences is targeting?

Assembly Biosciences is developing innovative therapeutics targeting serious viral diseases, including helicase-primase inhibitors for herpes simplex virus (HSV), an orally bioavailable hepatitis delta virus entry inhibitor, and a next-generation capsid assembly modulator for hepatitis B virus.

How have research and development expenses changed for Assembly Biosciences?

Research and development expenses increased to $47.563 million for the nine months ended September 30, 2025, up from $41.653 million in the same period of 2024, reflecting continued investment in its product pipeline.

What is the impact of the recent equity offerings on Assembly Biosciences' common stock?

The recent equity offerings led to an increase in common stock outstanding. As of November 7, 2025, there were 15,817,140 shares of common stock outstanding, compared to 7,457,240 shares as of December 31, 2024.

What is Assembly Biosciences' strategy for future funding?

Assembly Biosciences intends to obtain any additional funding it requires through strategic relationships, public or private equity or debt financings, grants, or other arrangements, as it continues to incur substantial losses from operations.

What is the primary risk factor for Assembly Biosciences despite the recent funding?

Despite the recent funding, a primary risk factor for Assembly Biosciences remains its ability to successfully initiate and complete clinical studies for its therapeutic product candidates in anticipated timeframes, and for safety and efficacy data to warrant further development.

Risk Factors

Industry Context

Assembly Biosciences operates in the highly competitive and capital-intensive biotechnology sector, focusing on developing novel therapies. The industry is characterized by long development cycles, significant R&D investment, and stringent regulatory hurdles. Success hinges on innovation, clinical trial outcomes, and securing substantial funding to advance pipeline candidates through development and commercialization.

Regulatory Implications

As a clinical-stage biopharmaceutical company, ASMB is subject to rigorous oversight by regulatory bodies like the FDA. Any delays in clinical trials, adverse findings, or failure to obtain regulatory approval for its drug candidates could severely impact its development timeline and commercial prospects. Compliance with evolving healthcare regulations is also critical.

What Investors Should Do

  1. [object Object]
  2. [object Object]
  3. [object Object]
  4. [object Object]

Key Dates

Glossary

Going Concern
An accounting assumption that a company will continue to operate for the foreseeable future. If substantial doubt exists, it must be disclosed. (The company's recent capital raise resolved prior substantial doubt about its ability to continue as a going concern.)
Underwritten Offering
A type of securities offering where an underwriter (typically an investment bank) buys the securities from the issuer and resells them to the public. (ASMB raised $175.0 million through this type of offering, significantly improving its liquidity.)
Collaboration Revenue
Revenue generated from partnerships or agreements with other companies, often involving shared research, development, or commercialization efforts. (This is a key revenue stream for ASMB, showing significant growth from related-party agreements.)
Net Cash Used in Operating Activities
The amount of cash a company has spent on its core business operations over a period. A negative number indicates cash outflow. (An increase in net cash used in operating activities to $55.330M for the nine months indicates a higher operational burn rate.)

Year-Over-Year Comparison

Compared to the prior year, Assembly Biosciences has significantly improved its liquidity position, raising $175.0 million in August 2025 to reach $232.6 million in cash and cash equivalents, thereby resolving going concern doubts. Collaboration revenue has seen robust growth, increasing by over 57% year-over-year for the quarter to $10.789 million. However, research and development expenses have also risen to $47.563 million for the nine-month period, reflecting continued investment in its pipeline. The net loss has slightly narrowed, but the net cash used in operating activities has increased, indicating a higher operational burn rate despite improved revenue.

Filing Stats: 4,429 words · 18 min read · ~15 pages · Grade level 17.5 · Accepted 2025-11-10 16:15:51

Key Financial Figures

Filing Documents

Financial Statements

Financial Statements 2 Condensed Consolidated Balance Sheets at September 30, 2025 (unaudited) and December 31, 2024 2 Condensed Consolidated Statements of Operations and Comprehensive Loss for the Three and Nine Months Ended September 30, 2025 and 2024 (unaudited) 3 Condensed Consolidated Statements of Changes in Stockholders' Equity for the Three and Nine Months Ended September 30, 2025 and 2024 (unaudited) 4 Condensed Consolidated Statements of Cash Flows for the Nine Months Ended September 30, 2025 and 2024 (unaudited) 6 Notes to the Condensed Consolidated Financial Statements (unaudited) 7 Item 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 17 Item 3.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 29 Item 4.

Controls and Procedures

Controls and Procedures 29 PART II: OTHER INFORMATION 30 Item 1.

Legal Proceedings

Legal Proceedings 30 Item 1A.

Risk Factors

Risk Factors 30 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 45 Item 3. Defaults Upon Senior Securities 45 Item 4. Mine Safety Disclosures 45 Item 5. Other Information 45 Item 6. Exhibits 46

SIGNATURES

SIGNATURES 47 References to Assembly Biosciences, Inc. Throughout this Quarterly Report on Form 10-Q, the "Company," "Assembly," "we," "us," and "our," except where the context requires otherwise, refer to Assembly Biosciences, Inc. and its consolidated subsidiaries, and "board of directors" refers to the board of directors of Assembly Biosciences, Inc.

Forward-Looking Statements

Forward-Looking Statements This Quarterly Report on Form 10-Q contains "forward-looking statements" that are subject to certain risks and uncertainties, including, without limitation, those set forth in Part I, Item 1A of our Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission (SEC) on March 20, 2025 (2024 Annual Report) and Part II, Item 1A of this Quarterly Report on Form 10-Q under the heading "Risk Factors," that could cause actual results to materially differ. Such risks and uncertainties include, among other things: our ability to realize the potential benefits of our collaboration with Gilead Sciences, Inc. (Gilead), including all financial aspects of the collaboration and equity investments; our ability to initiate and complete clinical studies involving our therapeutic product candidates, including studies contemplated by our collaboration with Gilead, in the currently anticipated timeframes or at all; safety and efficacy data from clinical or nonclinical studies may not warrant further development of our product candidates; clinical and nonclinical data may not differentiate our product candidates from other companies' candidates; our ability to maintain financial resources and secure additional funding necessary to continue our research activities, clinical studies and other business operations; the U.S. federal government shutdown and potential effects of changes in government regulation, including as a result of the change in U.S. administration in 2025; and results of nonclinical studies may not be representative of disease behavior in a clinical setting and may not be predictive of the outcomes of clinical studies. You are urged to consider statements that include the words may, will, would, could, should, might, believes, hopes, estimates, projects, potential, enable, expects, plans, anticipates, intends, continues, forecast, designed, goal or the negative of those words or other comparable words to be

- FINAN CIAL INFORMATION

PART I - FINAN CIAL INFORMATION

Financi al Statements

Item 1. Financi al Statements ASSEMBLY BIOSCIENCES, INC. CONDENSED CONSOLIDA TED BALANCE SHEETS (In thousands except for share amounts and par value) September 30, December 31, 2025 2024 (Unaudited) ASSETS Current assets Cash and cash equivalents $ 22,534 $ 38,344 Marketable securities 210,023 73,735 Accounts receivable from collaboration with a related party 912 — Prepaid expenses and other current assets 3,343 3,424 Total current assets 236,812 115,503 Property and equipment, net 229 284 Operating lease right-of-use (ROU) assets 2,644 3,069 Other assets 312 312 Total assets $ 239,997 $ 119,168 LIABILITIES AND STOCKHOLDERS' EQUITY Current liabilities Accounts payable $ 1,683 $ 585 Accrued research and development expenses 3,058 2,273 Other accrued expenses 5,728 6,862 Deferred revenue from a related party - short-term 42,363 37,622 Operating lease liabilities - short-term 548 461 Total current liabilities 53,380 47,803 Deferred revenue from a related party - long-term 1,715 35,378 Operating lease liabilities - long-term 2,207 2,628 Total liabilities 57,302 85,809 Commitments and contingencies Stockholders' equity Preferred stock, $ 0.001 par value; 5,000,000 shares authorized; no shares issued or outstanding — — Common stock, $ 0.001 par value; 150,000,000 shares authorized as of September 30, 2025 and December 31, 2024; 15,816,987 and 7,457,240 shares issued and outstanding as of September 30, 2025 and December 31, 2024, respectively 16 7 Additional paid-in capital 1,036,906 859,488 Accumulated other comprehensive loss ( 90 ) ( 211 ) Accumulated deficit ( 854,137 ) ( 825,925 ) Total stockholders' equity 182,695 33,359 Total liabilities and stockholders' equity $ 239,997 $ 119,168 See Accompanying Notes to Condensed Consolidated Financial Statements 2 ASSEMBLY

View on Read The Filing